<DOC>
	<DOC>NCT02258854</DOC>
	<brief_summary>The purpose of this study is to provide continued dosing of gevokizumab in order to obtain and assess long-term gevokizumab safety data.</brief_summary>
	<brief_title>An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<criteria>Completed either the X052130/CL378989005 or the X052131/CL378989006 study's masked D392 or OL224 completion day visits or had controlled ocular inflammation after having received study drug in Part 2 of study X052133 Discontinued from the previous study Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Uveitis</keyword>
	<keyword>Non-infectious Uveitis</keyword>
	<keyword>Intermediate Uveitis</keyword>
	<keyword>Posterior Uveitis</keyword>
	<keyword>Panuveitis</keyword>
	<keyword>Beh√ßet's disease uveitis</keyword>
</DOC>